Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
Innate Pharma announced the publication in Science Immunology of preclinical data for IPH6501, a tetra-specific NK cell engager targeting CD20 for B-NHL treatment. The study demonstrates that IPH6501 enhances NK cell proliferation and cytotoxicity, showing effectiveness against various B-NHL cell lines, including those with low CD20 density. In vivo studies confirmed its efficacy and ability to induce NK cell migration to tumor sites. The data revealed superior killing efficacy compared to T cell engagers while showing reduced toxicities. IPH6501 is currently being evaluated in a Phase 1/2 clinical trial for B-cell non-Hodgkin lymphoma.
Innate Pharma ha annunciato la pubblicazione su Science Immunology di dati preclinici per IPH6501, un attivatore di cellule NK tetra-specifico che mira a CD20 per il trattamento del B-NHL. Lo studio dimostra che IPH6501 potenzia la proliferazione e la citotossicità delle cellule NK, mostrando efficacia contro diverse linee cellulari di B-NHL, comprese quelle con bassa densità di CD20. Gli studi in vivo hanno confermato la sua efficacia e la capacità di indurre la migrazione delle cellule NK verso i siti tumorali. I dati hanno rivelato una maggiore efficacia nell'uccisione rispetto agli attivatori delle cellule T, mostrando al contempo una riduzione delle tossicità. Attualmente, IPH6501 è in fase di valutazione in un studio clinico di fase 1/2 per il linfoma non-Hodgkin a cellule B.
Innate Pharma anunció la publicación en Science Immunology de datos preclínicos para IPH6501, un activador de células NK tetra-específico dirigido a CD20 para el tratamiento del B-NHL. El estudio demuestra que IPH6501 mejora la proliferación y citotoxicidad de las células NK, mostrando efectividad contra varias líneas celulares de B-NHL, incluidas aquellas con baja densidad de CD20. Los estudios in vivo confirmaron su eficacia y capacidad para inducir la migración de células NK a los sitios tumorales. Los datos revelaron una eficacia de eliminación superior en comparación con los activadores de células T, mostrando al mismo tiempo una reducción de toxicidades. Actualmente, IPH6501 se está evaluando en un ensayo clínico de fase 1/2 para linfoma no Hodgkin de células B.
Innate Pharma는 B-NHL 치료를 위한 CD20을 목표로 하는 테트라-스페시픽 NK 세포 결합제 IPH6501의 전임상 데이터가 Science Immunology에 게재되었음을 발표했습니다. 이 연구는 IPH6501이 NK 세포의 증식과 세포독성을 향상시켜 낮은 CD20 밀도를 가진 다양한 B-NHL 세포주에 대해 효과를 나타냄을 보여줍니다. In vivo 연구를 통해 종양 부위로 NK 세포의 이동을 유도하는 효능이 확인되었습니다. 데이터는 T 세포 결합제에 비해 우수한 살해 효율성과 낮은 독성을 나타냈습니다. IPH6501은 현재 B세포 비호지킨 림프종을 위한 1/2상 임상시험에서 평가되고 있습니다.
Innate Pharma a annoncé la publication dans Science Immunology de données précliniques pour IPH6501, un activateur de cellules NK tétra-spécifique ciblant CD20 pour le traitement du B-NHL. L'étude démontre qu'IPH6501 améliore la prolifération et la cytotoxicité des cellules NK, montrant une efficacité contre diverses lignées cellulaires de B-NHL, y compris celles à faible densité de CD20. Les études in vivo ont confirmé son efficacité et sa capacité à induire la migration des cellules NK vers les sites tumoraux. Les données ont révélé une efficacité de destruction supérieure par rapport aux activateurs de cellules T, tout en montrant une réduction des toxicités. IPH6501 est actuellement évalué dans un essai clinique de phase 1/2 pour le lymphome non-Hodgkin à cellules B.
Innate Pharma hat die Veröffentlichung von präklinischen Daten zu IPH6501, einem tetra-spezifischen NK-Zell-Engager, der auf CD20 abzielt, zur Behandlung von B-NHL in Science Immunology angekündigt. Die Studie zeigt, dass IPH6501 die Proliferation und Zytotoxizität von NK-Zellen verbessert und gegen verschiedene B-NHL-Zelllinien, einschließlich solcher mit niedriger CD20-Dichte, wirksam ist. In-vivo-Studien bestätigten die Wirksamkeit und die Fähigkeit, die Migration von NK-Zellen zu Tumororten zu induzieren. Die Daten zeigten eine überlegene Tötungswirksamkeit im Vergleich zu T-Zell-Engagern und eine reduzierte Toxizität. IPH6501 wird derzeit in einer Phase 1/2-Studie für das B-Zell-Nicht-Hodgkin-Lymphom bewertet.
- Successful preclinical results published in prestigious Science Immunology journal
- IPH6501 demonstrated superior killing efficacy compared to T cell engagers
- Showed reduced toxicities compared to T cell therapies
- Effective against various B-NHL cell lines, including those with low CD20 density
- Already advanced to Phase 1/2 clinical trials
- None.
Insights
The publication in Science Immunology reveals promising preclinical data for IPH6501, a novel tetra-specific NK cell engager. The molecule shows several key advantages that could translate into clinical benefits:
- Enhanced NK cell activation and proliferation compared to existing T-cell therapies
- Demonstrated efficacy against B-NHL cells, including those with low CD20 expression
- Improved tumor targeting through NK cell migration to tumor sites
- Better safety profile compared to T-cell engager therapies
While these preclinical results are encouraging, investors should note that IPH6501 is still in early clinical development (Phase 1/2). The transition from preclinical to clinical success is not guaranteed. The molecule's potential market opportunity in B-NHL is significant, but competition from established therapies and other emerging approaches will be a key consideration.
- IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL
- IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients
- In vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to migrate and infiltrate tumors
- Results support clinical development of IPH6501 in R/R B-NHL
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate’s proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654).
The data published shows that IPH6501, also called CD20-NKCE-IL2v in the publication, boosts NK cell proliferation and cytotoxicity, showing activity against a range of B-NHL cell lines, including those with low CD20 density. In vivo studies in nonhuman primates and tumor mouse models further validated its efficacy and revealed that IPH6501 induces peripheral NK cell migration at the tumor site.
“These new findings underscore the remarkable potential of IPH6501 to transform the treatment landscape for B-NHL. IPH6501 showed greater killing efficacy over a T cell engager targeting CD20 in in vitro preclinical models while presenting reduced toxicities compared with those commonly associated with T cell therapies. We are particularly encouraged by results that reveal IPH6501’s ability to drive NK cell migration directly to tumor sites, highlighting its potential as a game-changer in immuno-oncology. These findings are a testament to the promise of NK cell therapies to deliver safer and more targeted solutions for patients in need,” commented Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma.
The data published further support the current clinical development plan of IPH6501 in Relapsed/Refractory B-NHL.
About ANKET®
ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.
About IPH6501
IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not a subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule, hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells.
IPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria, EHA 2023, Carrette, SITC 2024, Demaria et al, Science Immunology 2024).
IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: monoclonal antibodies, multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC).
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, several ANKET® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, www.innate-pharma.com, and public filings and reports filed with the
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241118258203/en/
For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Source: Innate Pharma SA
FAQ
What are the key findings of IPH6501's preclinical studies for IPHA stock?
What is the current development stage of Innate Pharma's IPH6501 (IPHA)?
How does Innate Pharma's IPH6501 (IPHA) differ from existing cancer treatments?
